- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
See full Important Safety Information below
Diagnosis Codes
ICD-10-CM codes are used to report diseases and conditions. These will be needed on the CMS-1500 form.
View More InformationPrintable Summary Sheet
This PDF provides a summary of CPT codes for GSK Vaccines.
View Summary SheetThis section provides the vaccine product codes as well as some common administration codes associated with immunization using SHINGRIX. Administration codes will vary based on the service provided. Please refer to your most up-to-date Current Procedural Terminology (CPT) and International Classification of Diseases (ICD) manuals for appropriate coding.
INDICATION
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).
| CPT Code |
Description [46] | NDCs* | ICD-10-CM Code [8]** |
|
|---|---|---|---|---|
| Adult dose: 0.5 mL |
90750 | SHINGRIX is supplied as 2 components: a single-dose vial of lyophilized gE antigen component (brown caps) and a single-dose vial of adjuvant suspension component (blue-green caps). | Z23 | |
| SHINGRIX is supplied as an outer package of 1 dose | ||||
| Lyophilized Antigen Vial: Adjuvant Suspension Vial: Outer Package: |
NDC 58160-828-01 NDC 58160-829-01 NDC 58160-819-12 | |||
| SHINGRIX is supplied as an outer package of 10 doses | ||||
| Lyophilized Antigen Vial: Adjuvant Suspension Vial: Outer Package: |
NDC 58160-828-03 NDC 58160-829-03 NDC 58160-823-11 |
| * | Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC. For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11. [14] |
| ** | With the implementation of ICD-10-CM, all vaccine-related encounters are reported as code Z23 for all vaccines given. |
| Immunization Administration Codes (CPT) [6] | |
|---|---|
| CPT | Immunization administration through 18 years of age with counseling by physician or other qualified healthcare professional |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid) |
| +90472 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) |
| Adapted from American Medical Association. CPT 2016 Professional Edition. | |
If a vaccine has multiple components, then 90460 should be reported once in conjunction with 90461 for each additional vaccine/toxoid component contained within that vaccine. [6]
IMPORTANT SAFETY INFORMATION
- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
- Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
- SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients
All trademarks are the property of their respective owners.
826733R0 October 2017
Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.
Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.
You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.
This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
©2017 GSK group of companies or its licensor. Produced in USA.
